The stock of Zomedica Corp (ZOM) has seen a 0.62% increase in the past week, with a -7.74% drop in the past month, and a -5.72% decrease in the past quarter. The volatility ratio for the week is 3.04%, and the volatility levels for the past 30 days are at 3.44% for ZOM. The simple moving average for the past 20 days is -3.25% for ZOM’s stock, with a -12.84% simple moving average for the past 200 days.
Is It Worth Investing in Zomedica Corp (AMEX: ZOM) Right Now?
The stock has a 36-month beta value of 1.06. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZOM is 962.66M, and at present, short sellers hold a 4.60% of that float. On December 23, 2024, the average trading volume of ZOM was 5.17M shares.
ZOM) stock’s latest price update
The stock of Zomedica Corp (AMEX: ZOM) has decreased by -3.39 when compared to last closing price of 0.13.Despite this, the company has seen a gain of 0.62% in its stock price over the last five trading days. accesswire.com reported 2024-12-23 that With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica’s canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum.
Analysts’ Opinion of ZOM
Many brokerage firms have already submitted their reports for ZOM stocks, with Dawson James repeating the rating for ZOM by listing it as a “Buy.” The predicted price for ZOM in the upcoming period, according to Dawson James is $6 based on the research report published on January 06, 2023 of the previous year 2023.
ZOM Trading at -3.58% from the 50-Day Moving Average
After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.02% of loss for the given period.
Volatility was left at 3.44%, however, over the last 30 days, the volatility rate increased by 3.04%, as shares sank -6.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.48% lower at present.
During the last 5 trading sessions, ZOM rose by +0.75%, which changed the moving average for the period of 200-days by -13.98% in comparison to the 20-day moving average, which settled at $0.1251. In addition, Zomedica Corp saw -39.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZOM starting from Blair Anthony K, who purchase 150,000 shares at the price of $0.12 back on Nov 08 ’24. After this action, Blair Anthony K now owns 400,000 shares of Zomedica Corp, valued at $18,450 using the latest closing price.
POWERS JOHNNY D, the Director of Zomedica Corp, purchase 100,000 shares at $0.12 during a trade that took place back on Nov 11 ’24, which means that POWERS JOHNNY D is holding 2,425,000 shares at $12,100 based on the most recent closing price.
Stock Fundamentals for ZOM
Current profitability levels for the company are sitting at:
- -1.43 for the present operating margin
- 0.55 for the gross margin
The net margin for Zomedica Corp stands at -2.33. The total capital return value is set at -0.19. Equity return is now at value -26.82, with -25.43 for asset returns.
Based on Zomedica Corp (ZOM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -22.8.
Currently, EBITDA for the company is -29.39 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 4.15. The receivables turnover for the company is 11.2for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.82.
Conclusion
To sum up, Zomedica Corp (ZOM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
